Clinical Trials Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Oct 15, 2022; 13(10): 888-899
Published online Oct 15, 2022. doi: 10.4239/wjd.v13.i10.888
Metabonomics fingerprint of volatile organic compounds in serum and urine of pregnant women with gestational diabetes mellitus
Si-Ri-Gu-Leng Sana, Guang-Min Chen, Yang Lv, Lei Guo, En-You Li
Si-Ri-Gu-Leng Sana, Guang-Min Chen, Yang Lv, Lei Guo, En-You Li, Department of Anesthesiology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, China
Author contributions: Sana SRGL, Chen GM, Lv Y, Guo L, and Li EY designed the research study; Sana SRGL, Chen GM, Lv Y, and Guo L performed the research, and contributed new reagents and analytic tools; Sana SRGL analyzed the data and wrote the manuscript; all authors have read and approved the final manuscript.
Institutional review board statement: The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Harbin Medical University.
Clinical trial registration statement: This study is registered with the Chinese Clinical Trial Registry (No. ChiCTR2000038703).
Informed consent statement: All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at lienyou_1111@163.com.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: En-You Li, PhD, Doctor, Professor, Department of Anesthesiology, The First Affiliated Hospital of Harbin Medical University, No. 23 Youzheng Street, Nangang District, Harbin 150001, Heilongjiang Province, China. lienyou_1111@163.com
Received: June 18, 2022
Peer-review started: June 18, 2022
First decision: July 14, 2022
Revised: July 23, 2022
Accepted: September 12, 2022
Article in press: September 12, 2022
Published online: October 15, 2022
ARTICLE HIGHLIGHTS
Research background

Gestational diabetes mellitus (GDM) is a metabolic disorder in which hyperglycemia develops during pregnancy in non-diabetic women.

Research motivation

Gas chromatography-mass spectrometry (GC-MS) was used to analyze changes in metabonomics in pregnant women with GDM and to explore the mechanism of cognitive function decline in pregnant women with GDM.

Research objectives

To study the cognitive function of pregnant women with GDM and to identify potential volatile markers to evaluate the cognitive impairment of pregnant women with GDM.

Research methods

Solid-phase microextraction GC-MS analysis was used to detect organic matter in plasma and urine samples. The statistical methods used were principal component analysis and partial least squares-discriminant analysis.

Research results

Differential volatile metabolites in the serum of pregnant women with GDM mainly included hexanal, 2-octen-1-ol, and 2-propanol. The differential volatile metabolites in the urine of pregnant women with GDM included benzene, cyclohexanone, 1-hexanol, and phenol.

Research conclusions

Of 2-propanol may be a potential volatile marker to evaluate the cognitive impairment of pregnant women with GDM.

Research perspectives

The study of perinatal cognitive decline is worthwhile, especially in women with GDM. The key is the prevention and treatment of the disease. Whether 2-propanol can be used as a therapeutic target requires further investigation.